S
SPYRE THERAPEUTICS INC.
NASDAQ: SYRE (Spyre Therapeutics, Inc.)
最近更新时间: 18小时之前15.76
0.26 (1.68%)
| 前收盘价格 | 15.50 |
| 收盘价格 | 15.53 |
| 成交量 | 506,667 |
| 平均成交量 (3个月) | 616,350 |
| 市值 | 951,172,736 |
| 价格/销量 (P/S) | 650.22 |
| 股市价格/股市净资产 (P/B) | 2.86 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -3.06 |
| 总债务/股东权益 (D/E MRQ) | 0.06% |
| 流动比率 (MRQ) | 8.06 |
| 营业现金流 (OCF TTM) | -169.86 M |
| 杠杆自由现金流 (LFCF TTM) | -68.57 M |
| 资产报酬率 (ROA TTM) | -25.34% |
| 股东权益报酬率 (ROE TTM) | -65.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Spyre Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.50 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 8.71% |
| 机构持股比例 | 106.07% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2025 | 4,018,101 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2025 | 2,127,205 |
| 52周波幅 | ||
| 中 | 45.00 (185.53%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Leerink Partners | 08 Apr 2025 | 45.00 (185.53%) | 购买 | 11.80 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合